a prospective, randomized, open study of oral Cry j1-galactomannan conjugate immunotherapy for Japanese cedar pollen allergy
- Conditions
- Japanese cedar pollen allergy
- Registration Number
- JPRN-UMIN000013408
- Lead Sponsor
- Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University
- Brief Summary
Participants receiving OIT treatment showed significant improvements in total symptom scores, medication score, and total symptom-medication scores through the pollen season compared with control group. The levels of allergen-specific serum IgG4 in individuals were significantly increased in the OIT group, but not the control group through cedar pollen season. Importantly, no severe adverse effects were observed in participants receiving OIT treatment. (Allergol Int 64:161-168, 2015) Participants receiving OIT showed significant improvements in the total QOL score and VAS throughout the pollen season compared with the control group. In addition, the mean total QOL score and VAS correlated in both groups during the pollen season.(Auris Nasus Larynx 43: 50-55, 2016)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Not provided
Exclusion criteria were as follows: severe asthma, chronic sinusitis, previous immunotherapy or ongoing immunotherapy with other allergens, treatment with B-blockers or participants on continuous corticosteroids, pregnancy or planned pregnancy, participation in another clinical trial, and the standard contraindications for immunotherapy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method